Serum IL-6 predicts immunotherapy-related adverse and outcome in advanced gastric and esophageal cancer patients with Anti-PD-1 treatment
Elevated serum IL-6 levels were associated with the incidence of irAEs, and higher IL-6 levels predicted worse prognosis in GAC and ESCC patients with ICIs treatment.
Authors
- Zhanjun Guo (ORCID: https://orcid.org/0000-0002-5111-5444)
- Pengqing Jiao
- Yue Zhao (ORCID: https://orcid.org/0000-0001-8834-1069)
- Hongfang Ma (ORCID: https://orcid.org/0009-0001-8080-6113)
- Shasha Zhang (ORCID: https://orcid.org/0000-0003-3431-7615)
- Fujun Wang (ORCID: https://orcid.org/0000-0003-2040-7484)
- Jianhua Wu (ORCID: https://orcid.org/0000-0003-1515-2309)
- Haixia Ding
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1553882
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27